

# Hospital for Advanced Medicine & Surgery Limited: Issuer rating of [ICRANP-IR] BBB-assigned; bank loan ratings reaffirmed

## December 11, 2023

# **Summary of rating action**

Instrument	Previous Rated Amount (NPR in million)	Current Rated amount (NPR in million)	Rating action	
Issuer Rating	-	NA	[ICRANP-IR] BBB-; assigned	
Long-term loans	853.74	853.74	[ICRANP] LBBB-; reaffirmed	
Short-term loans	20.00	20.00	[ICRANP] A3; reaffirmed	
Total	873.74	873.74		

# **Rating action**

ICRA Nepal has assigned an issuer rating of [ICRANP-IR] BBB- (pronounced ICRA NP Issuer Rating triple B minus) to Hospital for Advanced Medicine & Surgery Limited (HAMS or the company). Issuers with this rating are considered to have moderate degree of safety regarding timely servicing of financial obligations. The rating is only an opinion on the general creditworthiness of the rated entity and not specific to any debt instrument.

ICRA Nepal has also reaffirmed the bank loan ratings of HAMS at long-term loan rating of [ICRANP] LBBB- (pronounced ICRA NP L triple B minus) and a short-term loan rating of [ICRANP] A3 (pronounced ICRA NP A three) respectively.

#### Rationale

The rating action mainly factors in the company's good operational profile with steadily growing patient flow, which is also reflected in its revenue and margins' trajectory in recent years (notwithstanding the dip in FY2023 as the pandemic induced surge has subsided). HAMS has maintained a comfortable leverage ratio and satisfactory debt coverage metrics in recent years, as a majority of its capex has been funded through profit accruals. The rating action also factors in the positive demand outlook for the healthcare industry in Kathmandu Valley.

Nonetheless, the ratings remain constrained by the liquidity pressure on the company, stemming from the recent capex. The capex was funded through internal accruals and/or creditors which has drained the short-term liquidity cushion and is reflected in weak current ratio of 0.65 times as of mid-July 2023. ICRA Nepal also notes the rising competition in the fragmented healthcare industry as well as regulatory risks associated with the industry. Going forward, the company's ability to timely raised the proposed IPO (at proposed price), will remain essential for its incremental liquidity profile, considering the sizeable capex proposed by the management. The ability of the company to sustain the trajectory of revenue/margins improvement and maintain its capitalisation and coverage indicators will remain among the key rating sensitivities.

# **Key rating drivers**

## **Credit strengths**

Good operational profile – HAMS has been operational since 1998, albeit with modest scalability until the current promoter group took over the management in 2016. Thereafter, the added facilities in the hospital (including the shift to its current premises) and its improving brand recall have resulted in sharp revenue growth from FY2019 to FY2021. This was mainly on back of the consistent growth in total patient volume in last four years (CAGR of ~22%), notwithstanding the dip in FY2021 owing to the pandemic impact. While the occupancy has dipped in recent years (~47% for FY2023 as against ~64%



for FY2021), following the corrections from elongated length of stay for Covid patients, IPD patient volume also remains in an improving trend, which remains a positive.

Satisfactory financial profile – The company has reported healthy operating profit margin (OPM) of ~25% in FY2023, despite the gradual drop from the highest levels of ~34% in FY2021, which was mainly on account of high margin Covid induced revenues. ICRA Nepal expects the margins to largely stabilise around FY2023 levels. Given the good internal accruals and limited fresh debt addition in recent years, the company has reported satisfactory leverage levels with gearing of 1.1 times as on mid-July FY2023 while the debt service indicators also remained adequate with DSCR of 2.3 times in FY2023. The proposed IPO would lead to further improvements in the leverage and coverage metrics, which remains a positive.

Positive industry outlook; good location/infrastructure – Factors such as better affordability through increasing per capita income and growing medical insurance coverage, rising awareness and demand for healthcare, technological improvements in early diagnosis and treatment, and higher incidence of lifestyle diseases support the healthcare industry's prospects. The company's convenient location and its good infrastructure as a multi-speciality hospital amid the high population density in the Kathmandu valley remain positives for the company's incremental revenue prospects.

## **Credit challenges**

Liquidity profile – The company did not opt for term debt additions for its sizeable capex in recent years (~NPR 516 million from FY2021 to FY2023). The resultant funding mismatch has led to high reliance on creditors as reflected in creditor days of ~42 in FY2023 (albeit improved from ~91 days in FY2021) and hence a weak current ratio of 0.65 as of mid-July 2023. Any reduction in creditor support could lead to liquidity pressures, given the nominal cash balances and plans for further capex and investments in proposed associate companies (albeit now proposed to be mostly funded from IPO proceeds).

Intense competition and regulatory risk — HAMS faces intense competition from other large and established multi-speciality hospitals in the Kathmandu valley. In recent years, the healthcare services industry has grown highly competitive on account of the entry of large corporate hospitals and capacity enhancement by many established players. Going forward, an improvement in occupancy levels, especially in the newer segments, is highly dependent on the hospital's ability to retain and add reputed consultants in the respective fields, which could also remain a challenge in light of the increased competition in the healthcare sector. ICRA Nepal also takes note of the inherent regulatory risks associated with the healthcare sector, along with the company's relatively modest scale of operations (100-bed capacity) vis-à-vis other large corporate hospitals.

Analytical approach: For arriving at the ratings, ICRA Nepal has applied its rating methodologies as indicated below.

#### Links to the applicable criteria

<u>Issuer Rating Methodology</u>
Corporate Credit Rating Methodology

#### Link to the last rating rationale:

Rationale Hospital for Advanced Medicine & Surgery Limited Fresh BLR September 2023

## **About the Company**

Incorporated as a private limited company in January 1998, Hospital for Advanced Medicine & Surgery Limited (HAMS) was converted to a public limited company in July 2022. HAMS is a 100-bed licensed multi-specialty hospital located in Dhumbarahi, Kathmandu. The major promoters of HAMS are its chairman Mr. Ram Sharan Bhandari and his family members.



# **Key financial indicators**

Amounts in NPR million	FY2019	FY2020	FY2021	FY2022	FY2023
Amounts in NPR million	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
Operating income-OI (Revenues in NPR million)	378	680	1,438	1,553	1,396
OPBDITA/OI (%)	-13.7%	12.5%	34.2%	27.8%	25.3%
Total debt/tangible net worth (TNW; times)	2.6	3.6	1.8	1.4	1.1
Total outside liabilities/TNW (times)	4.4	4.7	2.5	1.9	1.5
Total debt/OPBDITA (times)	-15.2	13.6	2.0	2.2	2.4
Interest coverage (ICR; times)	-	3.7	6.2	5.7	4.8
DSCR (times)	-2.5	1.2	2.7	2.9	2.3
NWC/OI	-104%	-25%	-10%	-12%	-8%
Current ratio	0.3	0.4	0.5	0.5	0.6

Source: Company data

## **Analyst Contacts:**

**Mr. Sailesh Subedi** (Tel No. +977-1-4519910/20) sailesh@icranepal.com

Mr. Rajib Maharjan (Tel No. +977-1-4519910/20) rajib@icranepal.com

Mr. Utshav Bikram Malla (Tel No. +977-1-4519910/20) utshav.malla@icranepal.com

# **Relationship Contacts**

Ms. Barsha Shrestha (Tel No. +977-1-4519910/20) barsha@icranepal.com

## **About ICRA Nepal Limited**

ICRA Nepal Limited, the first credit rating agency of Nepal, is a subsidiary of ICRA Limited (ICRA) of India. It was licensed by the Securities Board of Nepal (SEBON) on October 3, 2012. ICRA Nepal is supported by ICRA Limited through a technical support services agreement, which envisages ICRA helping ICRA Nepal in areas such as rating process and methodologies, analytical software, research, training, and technical and analytical skill augmentation.

Our parent firm, ICRA Limited, was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment information and credit rating agency. Today, ICRA and its subsidiaries together form the ICRA Group of Companies.

For more information, visit <u>www.icranepal.com</u>

## **ICRA Nepal Limited**

Sunrise Bizz Park, 6th Floor, Dillibazar, Kathmandu, Nepal

Phone: +977 1 4519910/20 Email: info@icranepal.com Web: www.icranepal.com

All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA Nepal.

ICRA Nepal ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. The ICRA Nepal ratings are subject to a process of surveillance which may lead to a revision in ratings. Please visit our website (www.icranepal.com) or contact ICRA Nepal office for the latest information on ICRA Nepal ratings outstanding. All information contained herein has been obtained by ICRA Nepal from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of



any kind, and ICRA Nepal in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. All information contained herein must be construed solely as statements of opinion and ICRA Nepal shall not be liable for any losses incurred by users from any use of this publication or its contents